研究者詳細 - 秋山　有史

論文 - 秋山　有史

分割表示 251 件中 101 - 120 件目／全件表示 >>

肝静脈根部に挟まれるように近接する腫瘍に対する腹腔鏡下肝切除の有用性・安全性に関する検討

天野怜, 新田浩幸, 菊地晃司, 眞壁健二, 武田大樹, 梅邑晃, 菅野将史, 片桐弘勝, 秋山有史, 岩谷岳, 大塚幸喜, 佐々木章

日本内視鏡外科学会雑誌 ( (一社)日本内視鏡外科学会 ) 26 ( 7 ) MO055 - 1 2021年12月

当院で施行したDenver型腹腔-静脈シャント留置後のDIC治療

天野怜, 菊地晃司, 武田大樹, 梅邑晃, 菅野将史, 片桐弘勝, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

Japanese Journal of Acute Care Surgery ( 日本Acute Care Surgery学会 ) 11 ( 1 ) 143 - 143 2021年11月

小児外科専門医不在・不足地域での小児外科医療岩手県における小児外科医療の現状

鈴木信, 田金恵, 梅邑晃, 片桐弘勝, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本臨床外科学会雑誌 ( 日本臨床外科学会 ) 82 ( 増刊 ) S172 - S172 2021年10月

舌下神経麻痺による構音障害を契機に発見された骨転移を伴う進行胃癌の一例

石井勇吾, 秋山有史, 田金恵, 二階春香, 遠藤史隆, 馬場誠朗, 梅邑晃, 片桐弘勝, 鈴木信, 岩谷岳, 大塚幸喜, 新田浩幸, 肥田圭介, 佐々木章

日本臨床外科学会雑誌 ( 日本臨床外科学会 ) 82 ( 増刊 ) S609 - S609 2021年10月

W-ED tubeによる減圧および栄養管理が有用であった特発性食道破裂術後縫合不全の一例

田金恵, 秋山有史, 馬場誠朗, 遠藤史隆, 二階春香, 石井勇吾, 梅邑晃, 片桐弘勝, 鈴木信, 岩谷岳, 大塚幸喜, 新田浩幸, 肥田圭介, 佐々木章

日本臨床外科学会雑誌 ( 日本臨床外科学会 ) 82 ( 増刊 ) S954 - S954 2021年10月

Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer.

Ryosuke Fujisawa, Takeshi Iwaya, Fumitaka Endo, Masashi Idogawa, Noriyuki Sasaki, Hayato Hiraki, Shoichiro Tange, Tomomi Hirano, Yuka Koizumi, Masakazu Abe, Tomoko Takahashi, Mizunori Yaegashi, Yuji Akiyama, Mari Masuda, Akira Sasaki, Fumiaki Takahashi, Yasushi Sasaki, Takashi Tokino, Satoshi S Nishizuka

Carcinogenesis 42 ( 10 ) 1239 - 1249 2021年09月 [国際誌]

We investigated whether early circulating tumor DNA (ctDNA) changes, measured using digital PCR (dPCR), can predict later chemotherapy responses in esophageal squamous cell cancer (ESCC). We compared the dynamics of ctDNA and tumor volumes during chemotherapy in 42 ESCC. The accuracy of predictions of later chemotherapy responses were evaluated by the ratio of the variant allele frequency (VAF) of ctDNA (post-/pre-ctDNA) and the total tumor volume (post-/pre-volume) before and after an initial chemotherapy cycle using a receiver-operating characteristic curve analysis. Total positive and negative objective responses (ORs) were defined as either >50% or ≤50% reductions, respectively, in the total tumor volume at the end of first-line chemotherapy. Mutation screening of 43 tumors from 42 patients revealed 96 mutations. The pretreatment dPCR-ctDNA data were informative in 38 patients, using 70 selected mutations (1-3 per patient). The areas under the curve (AUCs) for the post-/pre-volume and post-/pre-ctDNA levels used in predicting the total OR were 0.85 and 0.88, respectively. The optimal cutoff value of post-/pre-ctDNA was 0.13. In 20 patients with post-/pre-volume ≥50%, the total OR could be predicted by the post-/pre-ctDNA with high accuracy; the AUC by post-/pre-ctDNA was higher than that by post-/pre-volume (0.85 vs 0.76, respectively). Patients with low post-/pre-ctDNA (n = 18) had a significantly better overall survival rate than those with high post-/pre-ctDNA (n = 20; P = 0.03). Early ctDNA changes after an initial cycle of chemotherapy predict later responses to treatment with high accuracy in ESCC patients.

DOI PubMed

食道癌盲腸転移の一例

田金恵, 秋山有史, 馬場誠朗, 遠藤史隆, 二階春香, 岩谷岳, 杉本亮, 木村祐輔, 肥田圭介, 菅井有, 佐々木章

日本食道学会学術集会プログラム・抄録集 ( (NPO)日本食道学会 ) 75回 246 - 246 2021年09月

減量・代謝改善手術の呼吸機能に対する効果

屋成信吾, 梅邑晃, 二階春香, 片桐弘勝, 木村聡元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本消化器外科学会総会 ( (一社)日本消化器外科学会 ) 76回 P270 - 4 2021年07月

安全な腹腔鏡下スリーブ状胃切除術実施を目指した周術期の多職種連携

高橋眞人, 梅邑晃, 二階春香, 屋成信吾, 片桐弘勝, 木村聰元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本外科系連合学会誌 ( 日本外科系連合学会 ) 46 ( 3 ) 390 - 390 2021年05月

metabolic syndromeに対する外科治療の現状と展開腹腔鏡下スリーブ状胃切除術における肥満2型糖尿病の長期改善効果と膵β細胞機能

梅邑晃, 二階春香, 新田浩幸, 片桐弘勝, 菅野将史, 武田大樹, 眞壁健二, 木村聰元, 秋山有史, 岩谷岳, 大塚幸喜, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 PD - 3 2021年04月

閉塞性睡眠時無呼吸に対する減量・代謝改善手術の効果

屋成信吾, 梅邑晃, 二階春香, 片桐弘勝, 木村聡元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 PS - 8 2021年04月

Circulating tumor DNAの初期変動を用いた食道癌化学療法効果予測に関する検討

藤澤良介, 岩谷岳, 遠藤史隆, 佐々木教之, 二階春香, 馬場誠朗, 秋山有史, 開勇人, 小泉優香, 阿部正和, 片桐弘勝, 木村聡元, 大塚幸喜, 井戸川雅史, 新田浩幸, 佐々木章, 佐々木泰史, 時野隆至, 西塚哲

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 SF - 1 2021年04月

生体肝移植後胆道狭窄症に対する予防と対策

片桐弘勝, 新田浩幸, 菅野将史, 梅邑晃, 武田大樹, 眞壁健二, 有吉佑, 木村拓, 木村聡元, 秋山有史, 岩谷岳, 大塚幸喜, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 SF - 7 2021年04月

日本人高度肥満患者における高度肝線維化予測因子の検討

二階春香, 梅邑晃, 片桐弘勝, 木村聡元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 PS - 5 2021年04月

腹腔鏡下スリーブ状胃切除術後の口腔内・腸内細菌叢の変化と減量・代謝改善効果

石岡秀基, 梅邑晃, 片桐弘勝, 木村聰元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 SF - 5 2021年04月

脾臓Side population細胞の幹細胞移植細胞としての利用

木村拓, 高原武志, 眞壁健二, 武田大樹, 梅邑晃, 菅野将史, 片桐弘勝, 木村聡元, 秋山有史, 岩谷岳, 大塚幸喜, 新田浩幸, 佐々木章

日本外科学会定期学術集会抄録集 ( (一社)日本外科学会 ) 121回 PS - 8 2021年04月

Cutaneous metastasis from esophageal basaloid squamous cell carcinoma: A case report.

Fumitaka Endo, Yuji Akiyama, Masazumi Onishi, Noriyuki Uesugi, Tamotsu Sugai, Akira Sasaki

International journal of surgery case reports 80 105621 - 105621 2021年03月 [国際誌]

INTRODUCTION AND IMPORTANCE: Basaloid squamous cell carcinoma (BSCC) of the esophagus is a relatively rare histologic variant of squamous cell carcinoma. Here, we reported a case of solitary cutaneous metastasis as the first symptom of esophageal BSCC and was successfully treated with multidisciplinary treatment. CASE PRESENTATION: A 67-year-old man visited a local hospital with symptoms of dysphagia and cutaneous nodules on his left shoulder. Fluorine-18 fluorodeoxyglucose positron emission tomography revealed hypermetabolic accumulations in the middle thoracic esophagus, right recurrent laryngeal nerve lymph node, and epidermis of the left shoulder. Esophagogastroscopy revealed an ulcerative and infiltrating type tumor in the middle thoracic esophagus. Based on histopathologic examination of the endoscopic biopsy and the resected cutaneous tumor, the patient was diagnosed as esophageal BSCC with cutaneous metastasis. The patient was treated with chemotherapy followed by chemoradiotherapy. The therapeutic effect was a complete response, which was sustained for 39 months. CLINICAL DISCUSSION: Review of previous literature in the PubMed database revealed only been two case reports on cutaneous metastasis of BSCC. Advanced BSCC of the esophagus with distant metastasis has a poor prognosis. Therefore, in our case, future careful follow-up is required. CONCLUSION: Esophageal BSCC with cutaneous metastasis can be successfully managed by multidisciplinary treatment, including local resection of the cutaneous metastasis, systemic chemotherapy, and chemoradiotherapy.

DOI PubMed

肝切除術における腹腔鏡下手術の有用性と問題点当科における腹腔鏡下肝切除術の適応と手術手技

新田浩幸, 片桐弘勝, 菅野将史, 梅邑晃, 武田大樹, 真壁健二, 秋山有史, 大塚幸喜, 佐々木章

日本内視鏡外科学会雑誌 ( (一社)日本内視鏡外科学会 ) 25 ( 7 ) SY7 - 1 2021年03月

Surgical outcomes of 118 complex laparoscopic liver resections: a single- center experience.

Yasushi Hasegawa, Hiroyuki Nitta, Takeshi Takahara, Hirokatsu Katagiri, Shoji Kanno, Akira Umemura, Yuji Akiyama, Takeshi Iwaya, Koki Otsuka, Akira Sasaki

Journal of hepato-biliary-pancreatic sciences 27 ( 12 ) 942 - 949 2020年12月 [国内誌]

BACKGROUND: Indications for laparoscopic liver resection (LLR) are continuously expanding. The Japanese Society of Hepato-Biliary-Pancreatic Surgery defines highly difficult hepatectomy as a procedure involving one or more sections (except for left lateral sectionectomy) or anatomical segmentectomy. This study aimed to assess the outcomes of complex LLR procedures and compare their technical difficulties, about which only a little is known to date. METHODS: We performed a retrospective review of the operative outcomes of 118 consecutive patients who underwent pure laparoscopic complex hepatectomy. The surgical outcomes, including operative times, blood loss amounts, and postoperative morbidity rates, were compared among complex LLR procedures. RESULTS: The overall median operative time was 280 minutes, and the median intraoperative blood loss was 86 mL. Two patients required conversion to open laparotomy (1.7%). The postoperative major morbidity rate was 11.0% Posterosuperior segmentectomy, right hemihepatectomy, and anterior sectionectomy required the longest operative times. Anterior and posterior sectionectomy resulted in the highest blood loss, and right hemihepatectomy and anterior sectionectomy resulted in the most complications. CONCLUSIONS: The surgical difficulties associated with complex LLR procedures vary. It is critical to recognize the specific risks and cautionary points to ensure patient safety and provide proper systemic training to surgeons.

DOI PubMed

Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: A case report.

Fumitaka Endo, Yuji Akiyama, Masazumi Onishi, Ryosuke Fujisawa, Noriyuki Sasaki, Haruka Nikai, Shigeaki Baba, Ryo Sugimoto, Toshimoto Kimura, Takeshi Takahara, Takeshi Iwaya, Koki Otsuka, Hiroyuki Nitta, Keisuke Koeda, Tamotsu Sugai, Akira Sasaki

International journal of surgery case reports 75 152 - 156 2020年09月 [査読有り] [国際誌]

INTRODUCTION: Primary malignant melanoma of the esophagus (PMME) is a rare disease with a poor prognosis. Here, we report a case of retroperitoneal recurrence of PMME successfully treated with the anti-programmed cell death 1 antibody, nivolumab. PRESENTATION OF CASE: A 70-year-old male with dysphagia was referred to our hospital. Esophagogastroscopy showed an elevated tumor in the lower thoracic esophagus. A histopathological examination of the biopsy revealed poorly differentiated squamous cell carcinoma. The patient was diagnosed with clinical T3N1M0 stage III esophageal squamous cell carcinoma and was treated with neoadjuvant chemotherapy followed by radical esophagectomy. A postoperative histopathological examination revealed that atypical cells with a brown pigment were scattered in the tumor. Immunohistochemical staining demonstrated positive expression of human melanoma black 45, melan A, and S100. A pathological diagnosis of PMME was confirmed. Sixteen months after surgery, abdominal computed tomography revealed solitary retroperitoneal recurrence in the lateral portion of the ascending colon. Fluorine-18 fluorodeoxyglucose positron emission tomography (PET) showed hypermetabolic accumulation with a maximum standardized uptake value of 5.8. The patient was treated with nivolumab (240 mg) every two weeks. After eight courses of nivolumab, abnormal accumulation of the retroperitoneal mass disappeared on PET, and this therapeutic effect continued for 20 months. CONCLUSIONS: Nivolumab was effective for recurrence of PMME in our case. There are few reports of treatment with nivolumab for PMME. Further studies are necessary to establish the usefulness of nivolumab for PMME in the future.

DOI PubMed

　前のページ - 次のページ　

<秋山 有史>

論文 - 秋山 有史

<秋山　有史>

論文 - 秋山　有史